High-efficacy therapies for treatment-naïve individuals with relapsing–remitting multiple sclerosis
L Freeman, EE Longbrake, PK Coyle, B Hendin… - CNS drugs, 2022 - Springer
There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …
action currently approved by the US Food and Drug Administration for the treatment of …
[HTML][HTML] The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis
RM Mattiesing, G Gentile, I Brouwer… - NeuroImage: Clinical, 2022 - Elsevier
Background White matter lesions and brain atrophy are both present early in multiple
sclerosis. However, the spatio-temporal relationship between atrophy and lesion processes …
sclerosis. However, the spatio-temporal relationship between atrophy and lesion processes …
Neurobiologische und behaviorale Marker der Verarbeitung stressbezogener und affektiv negativer Stimuli bei Multipler Sklerose und deren Zusammenhang mit dem …
KM Wakonig - 2022 - refubium.fu-berlin.de
Psychologischer Stress kann den Schweregrad von Multipler Sklerose (MS) beeinflussen.
Die peripher-physiologische Stresssystemaktivität ist bei PatientInnen mit MS (PmMS) …
Die peripher-physiologische Stresssystemaktivität ist bei PatientInnen mit MS (PmMS) …
Facing the current challenges in multiple sclerosis lesions: from automated segmentation to assessing the role of inflammation in neurodegeneration
G Gentile - 2022 - flore.unifi.it
Multiple sclerosis (MS) is characterized by the concomitant presence of focal areas of
inflammation (lesions) and diffuse damage and neurodegeneration (atrophy). Lesions …
inflammation (lesions) and diffuse damage and neurodegeneration (atrophy). Lesions …